A Study to Evaluate the Safety, Tolerability, and Immunogenicity of COVID-19 Vaccine, CT-COV-21 Extension Study

NCT05048849 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

274

Enrollment

INDUSTRY

Sponsor class

Conditions

Covid19 Vaccine

Interventions

BIOLOGICAL: MVC-COV1901(S protein with adjuvant)

Sponsor

Medigen Vaccine Biologics Corp.